Relevant Gold Corp. (RGC)
CNSX 
NASDAQ (CM) Primary CNSX Summary
RGC Chart
RGC Resources: More Likely To Appeal More To Income-Focused Investors
RGC Resources is a micro-cap natural gas utility with limited growth prospects and a small, stable service area. RGCO's earnings growth remains sluggish, with FY 2026 guidance implying just 1.2% year-over-year EPS growth and a PE of 15.7. The company offers a 4.04% forward dividend yield, supported by an 82-year dividend history and consistent annual payout increases.
RGC Resources Q3 Earnings Call Highlights
RGC Resources NASDAQ: RGCO reported fiscal 2026 third-quarter net income of about $550,000, or $0.05 per diluted share, as higher margins supported results despite uneven weather patterns, increased operating expenses and the loss of a large industrial customer.
RGC Resources Q2 Earnings Call Highlights
RGC Resources NASDAQ: RGCO reported higher second-quarter earnings for fiscal 2026, citing increased Roanoke Gas margins from new rates that took effect Jan. 1, higher earnings from its unconsolidated affiliate MVP and lower interest expense. The company also discussed operational headwinds, including the shutdown of a large customer's facility and damage at its LNG peak-shaving facility.
Relevant Gold Corp. (RGC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Relevant Gold Corp. ever had a stock split?
Relevant Gold Corp. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Yat-Gai Au CEO | CNSX Exchange | KYG7487R1002 ISIN |
| HK Country | 10 Employees | - Last Dividend | 16 Jun 2025 Last Split | 16 Jul 2021 IPO Date |
Overview
Regencell Bioscience Holdings Limited is a notable player in the field of Traditional Chinese Medicine (TCM) based in Hong Kong. Established in 2014, its core mission revolves around leveraging the ancient wisdom of TCM in conjunction with modern bioscience techniques. The company dedicates its resources to the research, development, and commercialization of innovative TCM solutions targeting a variety of health issues. With a particular focus on neurocognitive disorders and degeneration, such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), as well as infectious diseases, Regencell aims to fulfill a significant need in the healthcare sector. Headquartered in Causeway Bay, Hong Kong, Regencell stands as a beacon of innovation, merging traditional therapies with contemporary scientific research.
Products and Services
- TCM-based Therapies for Neurocognitive Disorders
At the heart of Regencell's product line are the TCM-based solutions designed specifically for managing and treating neurocognitive disorders such as ADHD and ASD. Utilizing traditional Chinese herbal formulas, these treatments are the result of exhaustive scientific research and development efforts, aiming to address the complexities of these disorders without the side effects often associated with conventional medications.
- TCM Solutions for Infectious Diseases
Expanding beyond neurocognitive health, Regencell also focuses on the creation and distribution of TCM products aimed at combating infectious diseases. These products are based on centuries-old recipes and knowledge, updated with modern bioscience to enhance their efficacy and safety. Regencell’s approach in this area demonstrates the versatility and potential of TCM in addressing contemporary health challenges.
